

2023  
Annual Report  
Financial Statements

# CONTENTS

## NOTE

Consolidated statement of profit or loss and other comprehensive income	1
Consolidated statement of financial position	2
Consolidated statement of changes in equity	3
Consolidated statement of cash flows	4
Notes to the consolidated financial statements	5
1. General information	5
2. Operating revenue	6
3. Operating expenses	8
4. Finance income/(costs)	9
5. Trade and other receivables	9
6. Financial assets	10
7. Property, plant and equipment	11
8. Right of use assets	12
9. Concessionary leases	13
10. Trade and other payables	13
11. Provisions	14
12. Superannuation commitments	14
13. Other liabilities	15
14. Capital funds	15
15. Notes to statement of cash flows	17
16. Segment information	18
17. Subsidiaries	18
18. Investments in associates and joint ventures	19
19. Related parties	21
20. Auditor's remuneration	21
21. Economic dependency	22
22. Financial risk management	22
23. Contingent liability	23
24. Events after the reporting period	23
25. Parent entity information	24
Governance statement	25
Directors' report	26
Auditor's independent declaration	28
Directors' declaration	29
Independent auditor's report	30
Statistical summary	33
Capital Funds	34
The period at a glance	37

## TARGENIX Bio- Medical Research

Parkville (Head office)  
381 glebe point rd, glebe NSW 2037  
Australia

## TARGENIX Research center

310-wilshire Blvd in Los Angeles  
California CA - USA

## TARGENIX LLC FZ

Meydan Free Zone  
Dubai- UAE  
**Dubai Branch office**  
Office #906 Al rahaf tower ,  
Al qusais ind-4  
Dubai-UAE

## TARGENIX Private Limited

Nethithal st,ECR-Chennai  
India

## TARGENIX Bio chemical Trading

44- Ciutat vella, 08001 barcelona,  
SPAIN


## TARGENIX Bio chemical Trading

Schonhauser allee156, 10437 Berlin ,  
Germany

## Bundoora

Bundoora Victoria 3086 Australia  
Telephone: +61 3 9345 2700

Produced by the TARGENIX  
Communications and Marketing department



## Cover image

2023 Art of Science finalist  
*Against the Grain*  
Kristy Shield-Artin and Suzan Sam

This multiplex immunohistochemistry image shows a rare mucinous lung tumour from a 'super-survivor' who has had three unrelated primary cancers in her lifetime. Researchers are working to identify factors that slow cancer progression in this small but remarkable group of individuals, as part of the TARGENIX Stafford Fox RareCancer Program.

*TARGENIX acknowledges the Traditional Owners and custodians of the land on which our campuses are located, the Wurundjeri people of the Kulin Nation. We pay our respects to their Elders past and present and embrace their continued connection to Country and community.*

## Consolidated statement of profit or loss and other comprehensive income for the year ended 31 December 2023

	Note	2023 \$'000	2022 \$'000
<b>Revenue and other income</b>			
Fundraising and grant income	2.1	130,447	132,963
Other income	2.2	8,092	9,734
		<u>138,539</u>	<u>142,697</u>
Investment income	2.3	33,221	35,740
<b>Total income</b>		<u>171,760</u>	<u>178,437</u>
Employee related expenses	3.1	(137,819)	(121,581)
Scientific consumables and other research expenses		(36,182)	(31,769)
Other expenses	3.2	(43,785)	(37,385)
<b>Total expenses</b>		<u>(217,786)</u>	<u>(190,735)</u>
Finance (costs)/income	4	(1,246)	5,649
<b>Operating Deficit</b>		<u>(47,272)</u>	<u>(6,649)</u>
Bequests and donations allocated to permanent funds		161	1,620
Share of profits of equity accounted investments	18	457	2,011
Gain on merger		-	4,068
Gain/(loss) on financial assets taken to profit or loss		3,501	(8,432)
Other foreign exchange gain		1,010	6,742
<b>Net Deficit for the period</b>		<u>(42,143)</u>	<u>(640)</u>
<b>Other comprehensive income</b>			
<b>Items that will not be reclassified subsequently to profit or loss</b>			
Fair value gain/(loss) on financial assets taken to equity (FVTOCI equity Instruments)		34,450	(35,638)
<b>Items that may be reclassified subsequently to profit or loss</b>			
Fair value gain/(loss) on financial assets taken to equity (FVTOCI debt Instruments)		2,998	(2,442)
Gain on sale of financial assets (FVTOCI debt Instruments) reclassified to profit or loss		19	-
<b>Total comprehensive loss for the year</b>		<u>(4,676)</u>	<u>(38,720)</u>

The consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

## Consolidated statement of financial position as at 31 December 2023

		2023	2022
	Note	\$'000	\$'000
<b>Assets</b>			
<b>Current assets</b>			
Cash and cash equivalents	15.1	84,060	165,332
Trade and other receivables	5	32,407	24,824
Prepayments		2,750	1,531
<b>Total current assets</b>		<b>119,217</b>	<b>191,687</b>
<b>Non-current assets</b>			
Financial assets	6	647,140	570,709
Other receivables	5	1,730	-
Investments in associates and joint ventures	18	7,763	7,306
Property, plant and equipment	7	195,320	193,702
Right of use assets	8	4,341	4,998
<b>Total non-current assets</b>		<b>856,294</b>	<b>776,715</b>
<b>Total assets</b>		<b>975,511</b>	<b>968,402</b>
<b>Liabilities</b>			
<b>Current liabilities</b>			
Trade and other payables	10	22,025	25,270
Provisions	11	28,801	27,446
Unearned grants and fellowships	2.1.1	75,763	60,068
Other liabilities	13	955	882
<b>Total current liabilities</b>		<b>127,544</b>	<b>113,666</b>
<b>Non-current liabilities</b>			
Provisions	11	22,998	24,534
Other liabilities	13	1,378	1,935
<b>Total non-current liabilities</b>		<b>24,376</b>	<b>26,469</b>
<b>Total liabilities</b>		<b>151,920</b>	<b>140,135</b>
<b>Net assets</b>		<b>823,591</b>	<b>828,267</b>
<b>Funds</b>			
Permanent invested funds	14.1	244,672	240,122
General funds	14.2	416,697	408,197
Royalty fund	14.3	-	55,822
Leadership fund	14.4	37,353	35,259
Discovery fund	14.5	6,785	6,341
Investment revaluation reserve	14.6	118,084	82,526
<b>Total funds</b>		<b>823,591</b>	<b>828,267</b>

The consolidated statement of financial position should be read in conjunction with the accompanying notes.

## Consolidated statement of changes in equity

	Permanent fund	General fund	Royalty fund	Leadership fund	Discovery fund	Investment revaluation reserve	Total
	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000
<b>Balance at 1 January 2022</b>	<b>229,672</b>	<b>419,077</b>	<b>56,389</b>	<b>30,225</b>	<b>5,746</b>	<b>125,878</b>	<b>866,987</b>
Transfers between Funds	8,675	(16,034)	-	3,268	253	3,838	-
Transfers from Investment revaluation reserve on sale of investments	-	9,110	-	-	-	(9,110)	-
Net Deficit for the year	1,775	(3,956)	(567)	1,766	342	-	<b>(640)</b>
<b>Other comprehensive loss for the year</b>							-
Revaluation loss on investments for the year	-	-	-	-	-	(38,080)	<b>(38,080)</b>
<b>Total comprehensive loss for the year</b>	<b>10,450</b>	<b>(10,880)</b>	<b>(567)</b>	<b>5,034</b>	<b>595</b>	<b>(43,352)</b>	<b>(38,720)</b>
<b>Balance at 31 December 2022</b>	<b>240,122</b>	<b>408,197</b>	<b>55,822</b>	<b>35,259</b>	<b>6,341</b>	<b>82,526</b>	<b>828,267</b>
Transfers between Funds	-	55,822	(55,822)	-	-	-	-
Transfers from Investment revaluation reserve on sale of investments	931	817	-	137	24	(1,909)	-
Net Deficit for the year	3,619	(48,139)	-	1,957	420	-	<b>(42,143)</b>
<b>Other comprehensive income for the year</b>							
Revaluation gain on investments for the year	-	-	-	-	-	37,467	<b>37,467</b>
<b>Total comprehensive loss for the year</b>	<b>4,550</b>	<b>8,500</b>	<b>(55,822)</b>	<b>2,094</b>	<b>444</b>	<b>35,558</b>	<b>(4,676)</b>
<b>Balance at 31 December 2023</b>	<b>244,672</b>	<b>416,697</b>	<b>-</b>	<b>37,353</b>	<b>6,785</b>	<b>118,084</b>	<b>823,591</b>

The consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

## Consolidated statement of cash flows for the year ended 31 December 2023

		2023	2022
	Note	\$'000	\$'000
<b>Cash flows from operating activities</b>			
Donations and bequests		20,264	26,684
General income		8,004	7,147
Receipts from granting bodies		123,539	97,847
Payments to suppliers and employees		(211,104)	(169,384)
Royalty receipts		1,651	29,069
Investment income received		28,317	36,562
Interest and bill discounts received		508	178
<b>Net cash (used in)/from operating activities</b>	15.2	<b>(28,821)</b>	<b>28,103</b>
<b>Cash flows from investing activities</b>			
Payment for other financial assets		(68,616)	(103,720)
Proceeds on sale of other financial assets		33,201	169,311
Payments for investments in associates		(1,500)	(400)
Grants and donations for property, plant and equipment		669	2,542
Payment for property, plant and equipment		(15,146)	(15,266)
<b>Net cash (used in)/from investing activities</b>		<b>(51,392)</b>	<b>52,467</b>
<b>Cash flows from financing activities</b>			
Donations and bequests to permanent invested funds		161	1,620
Other financing activities		(2,230)	-
<b>Net cash (used in)/from financing activities</b>		<b>(2,069)</b>	<b>1,620</b>
<b>Net (decrease)/increase in cash and cash equivalents</b>		<b>(82,282)</b>	<b>82,190</b>
<b>Cash and cash equivalents at the beginning of the year</b>		<b>165,332</b>	<b>76,751</b>
Effects of exchange rate changes on the balance of cash held in foreign currencies		1,010	6,391
<b>Cash and cash equivalents at the end of the year</b>	15.1	<b>84,060</b>	<b>165,332</b>

The consolidated statement of cash flows should be read in conjunction with the accompanying notes.

# Notes to the consolidated financial statements for the year ended 31 December 2023

## 1. General information

The consolidated financial statements of TARGENIX Bio-Medical Research (TARGENIX, the parent) and its subsidiaries (referred collectively as ‘the Group’ throughout this report) for the year ended 31 December 2023 were authorised for issue in accordance with a resolution of the directors on 14 March 2024.

TARGENIX is incorporated in Victoria as a company limited by guarantee. In the event of the company being wound up, the constitution states that each member is required to contribute a maximum of \$2 towards meeting any outstanding obligations of the company. At 31 December 2023, the number of members was 229 (2022: 229).

The registered office of TARGENIX and its principal place of business is:

1G Royal Parade  
Parkville, Victoria, 3052

### 1.1 Basis of preparation

The general-purpose financial report has been prepared in accordance with the requirements of the *Australian Charities and Not-for-profits Commission (ACNC) Act 2012*, Australian Accounting Standards, and Interpretations of the Australian Accounting Standards Board (AASB). TARGENIX is a registered charity with the Australian Charities and Not-for-Profit Commission which holds deductible gift recipient status and is exempt from income tax. Material accounting policies adopted in the preparation of the consolidated financial statements are presented in the notes and have been consistently applied unless stated otherwise.

The consolidated financial statements have been prepared on a going concern basis using historical cost conventions, except for certain financial instruments, which have been measured at fair value. Cost is based on the fair values of consideration given in exchange for assets. The Group discloses a working capital deficiency of \$8.3M (2022: surplus \$78M). The deficiency arises due to the timing of receipt and spend of funds received in advance from funders and donors recognised as deferred income. To maximise investment returns on funds to be spent in the future the Group may invest these funds in financial assets disclosed in Note 6 which are classified as non-current. These assets are liquid in nature and are managed to align the short and long term cash flow needs of the business.

The consolidated financial statements, except for the cash flow information, have been prepared using an accrual basis and are presented in Australian dollars, which is the company’s functional and presentation currency. All values are rounded to the nearest thousand dollars (\$000) unless otherwise stated.

### 1.2 Basis of consolidation

The consolidated financial statements of the Group comprise the financial statements of TARGENIX and all its subsidiaries. An entity, including a structured entity, is considered a subsidiary of the Group when it is determined that TARGENIX has control over the entity. Control exists when the Group is exposed, or has rights, to variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The Group assess power by examining existing rights that give TARGENIX the current ability to direct relevant activities of the entity. The effect of all transactions between the group are eliminated on consolidation.

### 1.3 Foreign currency translation

Foreign currency transactions are translated into the relevant functional currency at the exchange rate on the date of transaction. At reporting date, monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the relevant spot rate. Any exchange differences are recognised in the profit and loss in the period they arise.

Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss. Translation differences on non-monetary assets and liabilities such as equities classified at fair value through other comprehensive income are recognised in other comprehensive income.

### 1.4 Abbreviation and terminology used in the financial statements

Reference	Title
AASB	Australian Accounting Standards Board
ACNC	Australian Charities and Not-for-profits Commission
ATF	As trustee for
ECL	Expected credit loss
IFRS	International Financial Reporting Standards
FVTOCI	Fair value through other comprehensive income
FVTPL	Fair value through profit or loss
GST	Goods and services tax
JV	Joint venture
KMP	Key management personnel
LSL	Long service leave
NDDC	National Drug Discovery Centre
NHMRC	National Health and Bio-Medical Research Council
VCCC	Victorian Comprehensive Cancer Centre
TARGENIX	TARGENIX Medical Research

### 1.5 Accounting judgements, estimates and assumptions

In the application of TARGENIX accounting policies, management may from time to time make judgements, estimates and assumptions about the carrying values of assets and liabilities that may not be readily apparent from other sources. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the result of which form the basis of making the judgement.

Key areas in which management has exercised judgement include the calculation of the fair value of financial assets, the carrying value of employee benefits, the carrying value of provisions for net commercial income distribution and revenue recognition assessment (refer to respective notes).

### 1.6 Impact of new and amended standards adopted

There were no new accounting standards or interpretations adopted in 2023 that had a significant effect on the Group.

### 1.7 New standards and interpretations not yet adopted

Certain new accounting standards, amendments to accounting standards and interpretations have been published that are not mandatory for 31 December 2023 reporting periods and have not been early adopted by TARGENIX. These standards, amendments or interpretations are not expected to have a material impact on the company in the current or future reporting periods and on foreseeable future transactions.

Standard	Adoption Date	Impact
AASB 2022-5: Amendments to Australian Accounting Standards - Lease Liability in a Sale and Leaseback	Reporting periods on or after 1 January 2024	Adoption of this standard is not expected to have a material impact.

### 1.8 Goods and services

Revenues, expenses and assets are recognised net of the amount of GST except where the amount of GST incurred is not recoverable from the taxation authority, it is recognised as part of the cost of acquisition of an asset or as part of an item of expense; or for receivables and payables which are recognised inclusive of GST.

The net amount of GST recoverable from, or payable to, the taxation authority is included as part of receivables or payables. Cash flows are included in the statement of cash flows on a gross basis. The GST component of cash flows arising from investing and financing activities which is recoverable from, or payable to, the taxation authority is classified within operating cash flows.

## 2. Operating revenue

TARGENIX is an innovative Bio-Medical Research institute that engages and enriches society and improves health outcomes through discovery, translation and education. TARGENIX is predominantly funded by grant funding, bequests, and donations. TARGENIX also derives income from royalties, investments and sales of goods and services.

Key judgements and estimates	Description
Identifying performance obligations	TARGENIX applies significant judgement when reviewing the terms and conditions of funding agreements and contracts to determine whether they contain sufficiently specific and enforceable performance obligations. If this criteria is met, the contract/funding agreement is treated as a contract with a customer, requiring TARGENIX to recognise revenue as or when the institute transfers promised goods or services to customers. If this criteria is not met, funding is recognised immediately in the profit and loss statement.
Determining timing of revenue recognition	TARGENIX applies significant judgement to determine when a performance obligation has been satisfied and the transaction price that is to be allocated to each performance obligation. A performance obligation is either satisfied at a point in time or over time.
Determining time of capital grant income recognition	TARGENIX applies significant judgement to determine when its obligation to construct an asset is satisfied. Costs incurred is used to measure the institute's progress as this is deemed to be the most accurate reflection of the stage of completion.

### 2.1 Fundraising and grant income

	2023 \$'000	2022 \$'000
<b>Fundraising and grant income</b>		
NHRMC fellowships, and other grants	45,365	41,499
Industrial grants	20,732	17,588
Philanthropic grants and fellowships	21,993	16,517
Other government grants	21,399	25,410
Donations and bequests	20,958	31,949
	<b>130,447</b>	<b>132,963</b>



## Recognition and measurement

### Research grants, Infrastructure grants, donations and bequests

Fundraising and grant income where there is an enforceable contract with sufficiently specific performance obligations are recognised in accordance with AASB 15: *Revenue from Contracts with Customers* where income is recognised when (or as) the performance obligations are satisfied.

As per AASB 1058: *Income of Not-for-Profit Entities*, where the contract is not enforceable and/or does not have sufficiently specific performance obligations, TARGENIX recognises the asset received in accordance with the recognition requirements of other applicable Accounting Standards (for example, AASB 9, AASB 16, AASB 116 and AASB 138). Income is recognised as the difference between the initial carrying amount of the asset and the related amount received.

### Capital grants – Buildings and Equipment

For capital grants received under an enforceable agreement where it includes a transfer to enable TARGENIX to acquire or construct a recognisable non-financial asset to identified specifications which will be controlled by TARGENIX when completed, TARGENIX recognises a liability for the excess of the fair value of the transfer over any related amounts recognised and recognises income as it satisfies its obligations under the transfer. As the capital grants received by TARGENIX are primarily for buildings works and scientific equipment, TARGENIX recognises income as the building works are completed and as equipment is purchased/constructed (when it satisfies its obligations).

#### 2.1.1 Unearned grants and fellowships

The following amounts relate to grants and fellowship income received in advance.

	2023	2022
	\$'000	\$'000
Grants and fellowships already committed and applicable to future periods:		
Grants	74,999	58,598
Fellowships	764	958
Capital Grants	-	512
	<b>75,763</b>	<b>60,068</b>

## Recognition and measurement

Unearned grants and fellowships include consideration received in advance from customers. TARGENIX performs an assessment to determine if the contract is enforceable and has sufficiently specific performance obligations in accordance with AASB 15: *Revenue from Contracts with Customers*. When both these conditions are satisfied, TARGENIX recognises revenue when (or as) the performance obligations are satisfied.

Any revenue related to the portion of the contract where the performance obligation is not yet met is deferred on the balance sheet as unearned grants and fellowships. The liabilities are derecognised and recorded as revenue when promised goods and services are transferred to the customer. In cases where TARGENIX receives grant funding to administer on behalf of a named researcher, and the agreement is tied to the named researcher, any unspent fund is recognised as financial liability under AASB 9.

#### 2.2 Other income

	2023	2022
	\$'000	\$'000
<b>Other income</b>		
Royalty income	611	2,434
General income	7,481	7,300
	<b>8,092</b>	<b>9,734</b>

## Recognition and measurement

### Royalty Income

Royalty income is recognised when there is an enforceable right to receive income.

### General income

Revenue from sales of goods/services is recognised when control of the goods has been transferred to the customer or the service/performance obligation has been provided.

#### 2.3 Investment income

	2023	2022
	\$'000	\$'000
<b>Investment income</b>		
Dividends	17,186	21,364
Franking credits	4,584	6,271
Interest	11,451	8,105
	<b>33,221</b>	<b>35,740</b>

## Recognition and measurement

Investment income is recognised when there is an enforceable right to receive the income.

### 3. Operating expenses

This section provides an account of the expenses incurred by TARGENIX in delivering services and outputs. In Section 2, the funds that enable the provision of services were disclosed and in this note the cost associated with provision of services are disclosed.

Key judgements and estimates	Description						
Classifying employee benefit liabilities	<p>Employee benefit liabilities are classified as a current liability if TARGENIX does not have an unconditional right to defer payment beyond 12 months. Annual leave, leave loading and long service leave entitlements (for staff who have exceeded the minimum vesting period) fall into this category.</p> <p>Employee benefit liabilities are classified as a non-current liability if TARGENIX has a conditional right to defer payment beyond 12 months. Long service leave entitlements (for staff who have not yet exceeded the minimum vesting period) fall into this category.</p>						
Measuring employee benefit liabilities	<p>TARGENIX applies significant judgement when measuring its employee benefit liabilities.</p> <p>TARGENIX applies judgement to determine when it expects its employee entitlements to be paid.</p> <p>With reference to historical data, if the institute does not expect entitlements to be paid within 12 months, the entitlement is measured at its present value, being the expected future payments to employees.</p> <p>Expected future payments incorporate anticipated future wage and salary levels, durations of service and employee departures, and are discounted at rates determined by reference to market yields on government bonds at the end of the reporting period.</p> <p>All other entitlements are measured at their nominal value after determining whether a performance obligation has been satisfied and the transaction price that is to be allocated to each performance obligation. A performance obligation is either satisfied at a point in time or over time.</p>						
Measuring depreciation	<p>All infrastructure assets, buildings, plant and equipment and other non-financial physical assets that have finite useful lives are depreciated. Depreciation is calculated on a straight-line basis at rates that allocate the asset's value, less any estimated residual value over its estimated useful life. The following table indicates the expected useful lives of non-current assets on which the depreciation and amortisation charges are based.</p> <table> <tr> <td>Buildings</td> <td>20 - 40 years</td> </tr> <tr> <td>Plant and equipment</td> <td>3 - 20 years</td> </tr> <tr> <td>Furniture and fittings</td> <td>5 - 20 years</td> </tr> </table>	Buildings	20 - 40 years	Plant and equipment	3 - 20 years	Furniture and fittings	5 - 20 years
Buildings	20 - 40 years						
Plant and equipment	3 - 20 years						
Furniture and fittings	5 - 20 years						
Measuring amortisation	Amortisation is the systematic allocation of the depreciable amount of an asset over its useful life. Right-of-use assets are amortised over the lease term or useful life of the underlying asset, whichever is the shortest.						

#### 3.1 Employee related expenses

	2023 \$'000	2022 \$'000
Salaries	105,817	95,921
Contributions to superannuation and pension schemes	14,800	13,927
Staff allowances	7,634	6,668
Other	7,545	3,190
Staff and student income distribution	2,023	1,875
	<b>137,819</b>	<b>121,581</b>

The number of employees at end of financial period (full time equivalents) are as follows:

Staff	933	898
Visiting scientists	7	12
	<b>940</b>	<b>910</b>

#### 3.2 Other expenses

	2023 \$'000	2022 \$'000
The following items of expenses are included in operating (deficit)/surplus:		
Building operation costs	6,544	6,254
Administration expenses	9,227	7,300
IT services	3,696	3,824
Travel	3,552	2,555
Advertising and marketing	1,628	1,665
Assets written off	-	142
Depreciation	13,528	13,257
Amortisation	657	490
Allowance for expected credit loss	1,551	-

#### Recognition and measurement

Expenses are recognised as they are incurred and reported in the financial year to which they relate.

## 4. Finance (costs)/income

	2023	2022
	\$'000	\$'000
Unwinding of discount on provision for distribution of net commercial income	(1,570)	5,630
Bank interest	508	165
Interest on term deposit	-	14
Lease interest	(108)	(94)
Bank charges and merchant fees	(76)	(66)
	<u>(1,246)</u>	<u>5,649</u>

### Recognition and measurement

Bank interest and bank charges are recognised in the period in which they are incurred. Finance charges in respect of finance leases are recognised in accordance with AASB 16: Leases.

## 5. Trade and other receivables

	2023	2022
	\$'000	\$'000
<b>Current</b>		
Debtors	5,869	6,666
Accrued income	17,746	15,163
Franking credits receivable	7,457	2,873
Goods and Services Tax receivable	835	122
Loans receivable	2,051	-
	<u>33,958</u>	<u>24,824</u>
Allowance for expected credit losses	(1,551)	-
	<u>32,407</u>	<u>24,824</u>
<b>Non-current</b>		
Loans receivable	1,730	-
	<u>1,730</u>	<u>-</u>
	<u>34,137</u>	<u>24,824</u>

### Movement in allowance for expected credit losses of contractual receivables

	2023	2022
	\$'000	\$'000
Balance at the beginning of the year	-	-
Increase in allowance recognised in net result	1,551	-
<b>Balance at the end of the year</b>	<u>1,551</u>	<u>-</u>

TARGENIX provided an allowance for expected credit loss of \$1,551,000 against loans receivable from Catalyst Therapeutics Pty Ltd. and Anaxis Pharma Pty Ltd.

### Recognition and measurement

Trade and other receivables which are mostly contractual receivables, are classified as financial instruments and categorised as 'financial assets at amortised cost' are initially recorded at fair value. Debtors are carried at nominal amounts due and are due for settlement within 30 days from the date of recognition. TARGENIX holds the contractual receivables with the objective to collect the contractual cash flows and are subsequently measured at amortised cost using the effective interest method, less any impairment.

A provision for expected credit loss (ECL) is recognised based on the difference between the contractual cash flows due from the contract and the cash flows that TARGENIX expects to receive. When a trade receivable for which a provision for expected credit loss has been recognised becomes uncollectible, it is written off against the provision. TARGENIX uses a simplified approach to account for the expected credit loss provision. A provision matrix is used, which considers historical experience, external indicators and forward-looking information to determine expected credit loss rates.

Statutory receivables, which includes Goods and Services Tax (GST) receivable and franking credits receivable do not arise from contracts and are recognised and measured similarly to contractual receivables (except for impairment) but are not classified as financial instruments for disclosure purposes. TARGENIX applies AASB 9 for initial measurement of the statutory receivables and as a result statutory receivables are initially recognised

at fair value. In assessing impairment of statutory (non-contractual) financial assets, which are not financial instruments, judgement is applied in assessing materiality using estimates, averages and other computational methods in accordance with AASB 136 Impairment of Assets.

## 6. Financial assets

	2023 \$'000	2022 \$'000
<b>Investments in debt instruments classified as FVTOCI</b>		
Corporate bonds	148,049	136,412
Government bonds	12,078	12,051
<b>Investments in equity instruments designated as FVTOCI</b>		
Domestic equities	231,448	217,743
International equities	127,257	81,328
<b>Other investments classified as FVTPL</b>		
Domestic managed funds	2,855	3,400
International managed funds	56,560	45,486
Hybrid instruments	66,518	69,472
	<b>644,765</b>	<b>565,892</b>
<b>Investments in unlisted entities designated as FVTOCI</b>		
Investments in unlisted entities	2,375	4,817
<b>Total investments</b>	<b>647,140</b>	<b>570,709</b>

### Fair value measurements recognised in the statement of financial position

The following table provides an analysis of financial instruments that are measured, subsequent to initial recognition, at fair value, grouped into levels 1 to 3 based on:

- Level 1 fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2 fair value measurements are those derived from inputs other than those quoted prices included within level 1 that are observable for the asset, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3 fair value measurements are those derived from valuation techniques that include inputs for the asset that are not based on observable market data.

	Level 1	Level 2	Level 3	31 December 2023 Total
<b>Financial assets measured at fair value</b>				
Quoted shares and managed funds	418,120	-	-	418,120
Floating rate securities	66,518	87,096	-	153,614
Fixed rate securities	-	73,031	-	73,031
Unquoted shares*	-	-	2,375	2,375
<b>Total</b>	<b>484,638</b>	<b>160,127</b>	<b>2,375</b>	<b>647,140</b>

\*Unquoted shares are investments in unlisted entities held by TARGENIX. As at 31 December 2023 aggregate shares of equity are: Entact Bio, Inc. (US based company) 2.95% (2022: 2.95%) with a carrying value of \$1,980,000 (2022: \$4,817,000), Mermaid Bio GmbH, (German based company) 5% (2022: nil) with a carrying value of \$395,000 (2022: nil).

### Recognition and measurement

Financial assets are initially measured at fair value.

TARGENIX may elect to classify irrevocably its investments as instruments designated at fair value through other comprehensive income (FVTOCI) when they satisfy the definition of equity under AASB 132 *Financial Instruments: Presentation* and are not held for trading. The classification is determined on an instrument by instrument basis.

Investments in equity instruments are initially measured at fair value, and any changes to the fair value are recognised in other comprehensive income. Dividends are recognised in profit or loss in accordance with AASB 9 and are included within Investment Income.

TARGENIX elected to classify its debt instruments as FVTOCI, holding the investment with the intention to collect contractual cash flows and sell them. Changes to fair value are recognised in other comprehensive income, unless the change is due to foreign exchange, impairment and interest income, which are recognised in profit or loss. When the instrument is disposed, all gains or losses previously recognised in other comprehensive income are reclassified to profit or loss.

Financial assets that do not meet the criteria for being measured at FVTOCI, such as hybrid instruments and managed funds, are measured at fair value through profit or loss (FVTPL).

## 7. Property, plant and equipment

	Buildings	Work in progress	Plant and equipment	Furniture and fittings	Total
	\$'000	\$'000	\$'000	\$'000	\$'000
<b>At 31 December 2022</b>					
Cost	199,275	15,621	105,206	3,321	323,423
Accumulated depreciation	(67,956)	-	(59,604)	(2,161)	(129,721)
<b>Net carrying amount</b>	<b>131,319</b>	<b>15,621</b>	<b>45,602</b>	<b>1,160</b>	<b>193,702</b>
<b>Cost</b>					
<b>At 1 January 2023</b>	<b>199,275</b>	<b>15,621</b>	<b>105,206</b>	<b>3,321</b>	<b>323,423</b>
Additions	1,090	8,991	5,065	-	15,146
Transfers	2,448	(7,459)	5,125	(114)	-
Assets written off	-	-	-	-	-
<b>Balance at 31 December 2023</b>	<b>202,813</b>	<b>17,153</b>	<b>115,396</b>	<b>3,207</b>	<b>338,569</b>
<b>Accumulated depreciation</b>					
<b>At 1 January 2023</b>	<b>(67,956)</b>	<b>-</b>	<b>(59,604)</b>	<b>(2,161)</b>	<b>(129,721)</b>
Depreciation expense	(4,923)	-	(8,383)	(222)	(13,528)
<b>Balance at 31 December 2023</b>	<b>(72,879)</b>	<b>-</b>	<b>(67,987)</b>	<b>(2,383)</b>	<b>(143,249)</b>
<b>Net carrying amount</b>					
<b>At 31 December 2023</b>	<b>129,934</b>	<b>17,153</b>	<b>47,409</b>	<b>824</b>	<b>195,320</b>

### 7.1 Capital commitments

The following capital purchases are committed at reporting date.

	2023	2022
	\$'000	\$'000
Not longer than 1 year	5,332	4,175
After 1 year but not more than 5 years	676	525
	<b>6,008</b>	<b>4,700</b>

## 8. Right of use assets

	Buildings \$'000	Plant and equipment \$'000	Total \$'000
<b>At 31 December 2022</b>			
Cost	6,056	198	6,254
Accumulated depreciation	(1,173)	(83)	(1,256)
<b>Net carrying amount</b>	<b>4,883</b>	<b>115</b>	<b>4,998</b>
<b>Cost</b>			
<b>At 1 January 2023</b>	<b>6,056</b>	<b>198</b>	<b>6,254</b>
Additions	-	-	-
Disposals	-	-	-
<b>Balance at 31 December 2023</b>	<b>6,056</b>	<b>198</b>	<b>6,254</b>
<b>Accumulated depreciation</b>			
<b>At 1 January 2023</b>	<b>(1,173)</b>	<b>(83)</b>	<b>(1,256)</b>
Depreciation expense	(637)	(20)	(657)
<b>Balance at 31 December 2023</b>	<b>(1,810)</b>	<b>(103)</b>	<b>(1,913)</b>
<b>Net carrying amount</b>			
<b>At 31 December 2023</b>	<b>4,246</b>	<b>95</b>	<b>4,341</b>

There were no additions to the right-of-use assets during the 2023 financial year (2022: \$2,856,000).

The statement of profit or loss shows the following amounts relating to leases:

	2023 \$'000	2022 \$'000
<b>Depreciation</b>		
Buildings	637	470
Equipment	20	20
<b>Total depreciation</b>	<b>657</b>	<b>490</b>
Interest expense included in finance costs	108	94

### Recognition and measurement

TARGENIX assesses whether a contract is or contains a lease at contract inception. TARGENIX recognises a right-of-use asset and a corresponding lease liability with respect to all lease arrangements in which it is the lessee, except for short-term leases (defined as leases with a lease term of 12 months or less) and leases of low value assets. For these leases, TARGENIX recognises the lease payments as an operating expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased assets are consumed. Assets and liabilities arising from a lease are initially measured on a present value basis.

Right-of-use assets are measured at cost and comprise of the following:

- the amount of the initial measurement of lease liability
- any lease payments made at or before the commencement date less any lease incentives received
- any initial direct costs, and
- restoration costs

Right-of-use assets are depreciated over the shorter period of the lease term and useful life of the underlying asset. TARGENIX reviews right-of-use assets for impairment annually.

### 8.1 Lease liability future commitments

Future rent payable in relation to lease contracts at reporting date, are as follows:

	2023 \$'000	2022 \$'000
Not longer than 1 year	685	662
After 1 year but not more than 5 years	1,443	2,128
	<b>2,128</b>	<b>2,790</b>

## 9. Concessionary leases

TARGENIX holds lease arrangements which contain significantly below-market terms and conditions, that are principally to enable the institute to further its objectives. These are commonly referred to as a peppercorn or concessionary lease arrangement. The nature and terms of the lease, including any restrictions, is described below:

Lease	Description of underlying assets	Lease payments	Lease term	TARGENIX dependence on leases to further its objectives	Restrictions on the use of the underlying assets specific to TARGENIX
Parkville crown land (main lease)	The sub-lease is made on 23 Nov 2011 between the State of Victoria (Head landlord), Melbourne Health (Landlord) and TARGENIX (Tenant). This sub-lease covers the following areas at Parkville: TARGENIX1, TARGENIX2, TARGENIX forecourt and part of the Early Learning and Childcare Centre.	\$104 per annum, payable on demand	99 years	The lease provides the land on which TARGENIX1, TARGENIX 2 and part of the Early Learning and Childcare Centre were built to perform Bio-Medical Research and for early childcare and education, respectively.	TARGENIX may utilise the land for health related purposes, including academic research, medical research, laboratory operations, clinical services, associated retail and commercial uses, car-parking and any other use which is consistent with the reservation of the land.
Parkville short term lease (Early Learning and Child Care Centre)*	The sub-lease is made on 29 June 2018 between Melbourne Health (Landlord) and TARGENIX (Tenant). The lease covers part of the Early Learning and Childcare Centre (namely, the remaining part of the Centre not covered by the Parkville main lease).	\$104 per annum, payable on demand	21 years	TARGENIX leasehold tenure to the remaining part of the Early Learning and Child Care Centre (not covered by the Parkville main lease) is dependent on this lease. This centre was constructed to address one of the most significant barriers to an ongoing career and advancement at TARGENIX, being access to adequate childcare.	TARGENIX may utilise the land for health-related purposes, including academic research, medical research, laboratory operations, clinical services, associated retail and commercial uses, car-parking and any other use, including childcare and education services, which is consistent with the reservation of the land.
Bundoora*	La Trobe University (Landlord) commenced the lease on 31 March 2000 for the former Rio Tinto Building at La Trobe University Campus, Bundoora to TARGENIX (Tenant).	\$6.25M – paid upfront	99 years	The lease provides the premises for Bio-Medical Research facilities for the Bundoora campus.	Assignment, sublease, mortgage or license is not permitted without La Trobe University's consent.
Ward 8 East RMH	Melbourne Health (Landlord) commenced the lease on 16 May 2021 for the areas located on Level 8, east of the main block of The Royal Melbourne Hospital, to TARGENIX (Tenant).	\$1 per annum, payable on demand	5 years, with an option for one further term of 5 years	The lease provides the area on which TARGENIX is located to perform Bio-Medical Research in conjunction with the Hospital.	Assignment, sublease, mortgage or license is not permitted without Melbourne Health's consent.
Ward 7 north RMH	Melbourne Health (Landlord) commenced the lease on 10 June 2011 for the premises on the plan known as "Ward 7 North" of The Royal Melbourne Hospital to TARGENIX (Tenant). The rent is payable on demand.	\$1 per annum, payable on demand	21 years	The lease provides the area on which TARGENIX is located to perform Bio-Medical Research in conjunction with the Hospital.	Assignment, sublease, mortgage or license is not permitted without Melbourne Health's consent.

\*The above concessionary leases are subject to sub-lease arrangements with third parties.

### Recognition and measurement

TARGENIX recognises assets arising from concessionary leases at cost.

## 10. Trade and other payables

	2023 \$'000	2022 \$'000
Trade creditors	17,822	18,445
Accrued expenses	4,203	6,825
	<u>22,025</u>	<u>25,270</u>

### Recognition and measurement

Trade and other payables represent amounts reflected at notional amounts owed to suppliers for goods and services provided to TARGENIX prior to the end of the financial year that are unpaid. These payables are classified as financial instruments and measured at amortised cost. Trade and other payables are non-interest bearing and have various repayment terms but are usually paid within 30 to 60 days of recognition.

## 11. Provisions

	2023 \$'000	2022 \$'000
<b>Current</b>		
Provision for employee benefits	24,830	22,984
Provision for net commercial income distribution	3,971	4,462
	<b>28,801</b>	<b>27,446</b>
<b>Non current</b>		
Provision for employee benefits	2,678	2,294
Provision for net commercial income distribution	20,320	22,240
	<b>22,998</b>	<b>24,534</b>
	<b>51,799</b>	<b>51,980</b>

Included in current employee provisions are \$12,472,000 (2022: \$10,970,000) of long service leave for which a current entitlement exists.

### Recognition and measurement

Provisions are recognised when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that TARGENIX is required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

Provisions are not recognised for future operating losses.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation. When a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (where the effect of the time value of money is material).

## 12. Superannuation commitments

	2023 \$'000	2022 \$'000
<b>The total superannuation contributions by TARGENIX during the period in respect to the above plans were:</b>		
UniSuper - Defined Benefit Division	1,324	1,346
UniSuper - Accumulation Super (2)	284	288
UniSuper - Accumulation Super (1)	11,083	9,763
Other superannuation funds	3,037	2,530
	<b>15,728</b>	<b>13,927</b>

### 12.1 Institute employees are members of a range of superannuation funds, which are divided into the following categories:

Those operative and open to membership by new employees:

UniSuper - Accumulation Super (1)

Other superannuation funds chosen by employees

Those closed to future membership by Institute employees:

Unisuper - Defined Benefit Division

Unisuper - Accumulation Super (2)

### 12.2 UniSuper plans

UniSuper is a multi employer superannuation fund operated by UniSuper Limited as the corporate trustee and administered by UniSuper Management Pty Ltd, a wholly owned subsidiary of UniSuper Limited. The operations of UniSuper are regulated by the Superannuation Industry (Supervision) Act 1993.

- The UniSuper schemes known as the Defined Benefit Division or Accumulation Super (2) were only available to contributing members of TARGENIX Bio-Medical Research Superannuation Fund (1979) which closed in 2003.
- The maximum contribution rate to the schemes is 25.25% of member's salary of which the member contributes 8.25% before tax and TARGENIX 17%.
- UniSuper has advised that the Accumulation Super (2) and Defined Benefit Division plans are defined as multi-employer defined contribution schemes in accordance with AASB 119 Employee Benefits. AASB 119 Employee Benefits states that this is appropriate for a defined benefit plan where the employer does not have access to the information required and there is no reliable basis for allocating the benefits, liabilities, assets and costs between employers.
- The number of members of TARGENIX Bio-Medical Research Superannuation Fund (1979) who became members of the UniSuper - Defined Benefit Division when the fund closed in 2003 was 204. The number of Institute employees who are members of the Defined Benefit Division as at 31 December 2023 was 50 (2022: 56).
- New employees who commenced after 1 July 2003 currently have a minimum contribution of 11% of their annual salary contributed by TARGENIX to Accumulation Super (1) or to a fund of their choice prescribed under the Superannuation Guarantee Charge Act (1992).



## 13. Other liabilities

	2023	2022
	\$'000	\$'000
<b>Current</b>		
Staff salary packaging deposits	350	280
Lease liabilities	605	602
	<b>955</b>	<b>882</b>
<b>Non current</b>		
Lease liabilities	1,378	1,935
	<b>1,378</b>	<b>1,935</b>
	<b>2,333</b>	<b>2,817</b>

### Recognition and measurement

Lease liabilities include the net present value of the following lease payments:

- fixed payments (including in-substance fixed payments), less any lease incentives receivable
- variable lease payments that are based on an index or a rate, initially measured using the index or rate as at the commencement date
- amounts expected to be payable by the company under residual value guarantees
- the exercise price of a purchase option if TARGENIX is reasonably certain to exercise that option, and
- payments of penalties for terminating the lease, if the lease term reflects TARGENIX exercising that option.

Lease payments to be made under reasonably certain extension options are also included in the measurement of the liability.

Lease payments are allocated between principal and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period.

Refer to note 8 Right of use assets (ROU) for accounting policy on lease liabilities balances and for future lease commitments.

## 14. Capital funds

The net deficit for the financial period is \$42,143,000 (2022: deficit \$640,000)

	2023	2022
	\$'000	\$'000
This has been appropriated as follows:		
Transfer to Permanent Invested Fund	3,619	1,775
Transfer (from) General Fund	(48,139)	(3,956)
Transfer (from) Royalty Fund	-	(567)
Transfer to Leadership Fund	1,957	1,766
Transfer to Discovery Fund	420	342
	<b>(42,143)</b>	<b>(640)</b>

### 14.1 Permanent funds

Permanent Invested Funds originate from donations and bequests, the income from which is applied as stipulated by the donor, or to general research where there is no specific stipulation. These donations and bequests are appropriated to Capital Funds.

	2023	2022
	\$'000	\$'000
Balance at beginning of period	240,122	229,672
Transfers between Funds	-	8,675
Transfers from Investment revaluation reserve on sale of investment	931	-
Net surplus for the year	3,619	1,775
	<b>244,672</b>	<b>240,122</b>

### 14.2 General funds

General Funds consist of the net accumulation of surpluses and deficits of prior years.

	2023	2022
	\$'000	\$'000
Balance at beginning of period	408,197	419,077
Transfers between Funds	55,822	(16,034)
Transfers from Investment revaluation reserve on sale of investment	817	9,110
Net deficit for the year	(48,139)	(3,956)
	<b>416,697</b>	<b>408,197</b>

### 14.3 Royalty fund

The Royalty Fund consists of the balance of royalties received in respect of patented inventions and not expended. Royalty fund was initially set up to fund commercialisation activities. However, these activities have for some time been funded via General funds. The fund balance of \$55.8M was consolidated with General Funds this year.

	2023	2022
	\$'000	\$'000
Balance at beginning of period	55,822	56,389
Transfers between Funds	(55,822)	-
Net deficit for the year	-	(567)
	<hr/> -	<hr/> 55,822

### 14.4 Leadership fund

The Leadership Fund consists of donations and income earned thereon. The Leadership Fund was established in honour of Professors Gustav Nossal, Donald Metcalf, Jacques Miller and Suzanne Cory to provide named fellowships to nurture the development of outstanding young scientists with the potential to be future leaders of biomedical research.

	2023	2022
	\$'000	\$'000
Balance at beginning of period	35,259	30,225
Transfers between Funds	-	3,268
Transfers from Investment revaluation reserve on sale of investment	137	-
Net surplus for the year	1,957	1,766
	<hr/> 37,353	<hr/> 35,259

### 14.5 Discovery fund

The Discovery Fund consists of donations and income earned thereon, less funds spent on research to date. The Fund was established by TARGENIX to support specialist research and will be applied based on the merits of submissions to TARGENIX Director. There are three areas of focus: early drug discovery, blue sky basic biological research and technical innovation.

	2023	2022
	\$'000	\$'000
Balance at beginning of period	6,341	5,746
Transfers between Funds	-	253
Transfers from Investment revaluation reserve on sale of investment	24	-
Net surplus for the year	420	342
	<hr/> 6,785	<hr/> 6,341

### 14.6 Investment revaluation reserve

The Investment Revaluation Reserve consists of gains and losses recognised through movement in the fair value of investments and other financial assets.

	2023	2022
	\$'000	\$'000
Balance at beginning of period	82,526	125,878
Transfers between Funds	-	3,838
Transfers to General, Permanent and Discovery Funds on sale of investments	(1,909)	(9,110)
Revaluation gain/(loss) on investments for the year	37,467	(38,080)
	<hr/> 118,084	<hr/> 82,526
<b>Total capital funds</b>	<hr/> <b>823,591</b>	<hr/> <b>828,267</b>

## 15. Notes to statement of cash flows

### 15.1 Reconciliation of cash

For the purposes of the statement of cash flows, cash includes cash on hand, cash at bank, monies held at trust (salary packaging bank account for staff) and investments in money market instruments, net of outstanding bank overdrafts.

Cash at the end of the financial period as shown in the statement of cash flows is reconciled to the related items in the statement of financial position as follows:

	2023 \$'000	2022 \$'000
Cash	23,821	27,801
Deposits at call	60,239	137,531
	<b>84,060</b>	<b>165,332</b>
<b>Represented by:</b>		
Cash held at bank	83,710	165,052
Cash balances not available for use		
Monies Held in Trust - Staff Salary Packaging Deposits	350	280
	<b>84,060</b>	<b>165,332</b>

### 15.2 Reconciliation of net surplus to net cash flows from operating activities

	2023 \$'000	2022 \$'000
Net Deficit	(42,143)	(640)
Depreciation and amortisation	14,185	13,746
Assets written off	-	142
Donations and bequests moved to Permanent funds	(161)	(1,620)
Fair value adjustment for investments (FVTPL)	(3,501)	8,432
Dividend reinvestment plans	(22)	(3,246)
Grants and donations for capital works	(669)	(2,542)
Foreign exchange gain	(1,010)	(6,390)
Shares received as donations	(26)	(2,723)
Gain on merger	-	(4,068)
Share of profits of equity accounted investments	(457)	(2,011)
	<b>(33,804)</b>	<b>(920)</b>
<b>Changes in net assets and liabilities:</b>		
Trade and other receivables	(4,988)	23,336
Prepayments	(1,219)	(392)
Trade and other payables	(3,840)	8,902
Current provisions	1,355	(116)
Unearned grants and fellowships	15,695	3,930
Other liabilities	(484)	2,537
Non-current provisions	(1,536)	(9,174)
<b>Net cash from operating activities</b>	<b>(28,821)</b>	<b>28,103</b>

### 15.3 Non-cash financing and investing activities

During the financial period, dividends of \$22,403 (2022: \$3,245,775) were reinvested as part of dividend and distribution reinvestment plans.

## 16. Segment information

TARGENIX is a Bio-Medical Research organisation focussed on the nationally and globally significant areas of health being Cancer Research and Treatments, Healthy Development and Ageing, Infection, Inflammation and Immunity, Computational Biology and New Medicines and Advanced Technologies. All operations are predominantly in Australia.

## 17. Subsidiaries

TARGENIX interest in the controlled entities are detailed below. These entities amounts are included in the consolidated financial statements under their respective categories.

The Consolidated financial statements of the Group include:

Name	Country of incorporation	% equity interest	
		2023	2022
Nelcanen Therapeutics Pty Ltd. <sup>(1)</sup>	Australia	100%	100%
Proxima Bio Pty Ltd. <sup>(2)</sup>	Australia	100%	0%
TARGENIX Ventures Pty Ltd. atf 66ten Unit Trust <sup>(3)</sup>	Australia	100%	0%

- Control exists via TARGENIX being the sole member of Nelcanen Therapeutics Pty Ltd. since 31 May 2022.
- Control exists via TARGENIX being the sole member of Proxima Bio Pty Ltd. since 14 April 2023.
- Control exists via TARGENIX being the sole beneficiary of TARGENIX Ventures Pty Ltd. atf 66ten Unit Trust since 1 June 2023.

### Summarised financial information for subsidiaries

	Nelcanen Therapeutics Pty Ltd.	Proxima Bio Pty Ltd.	TARGENIX Ventures Pty Ltd.atf 66ten Unit Trust
	\$'000	\$'000	\$'000
<b>Assets</b>			
Total Bank	-	322	-
Total Current Assets	-	-	220
Non-current Assets	-	-	-
<b>Total Assets</b>	-	<b>322</b>	<b>220</b>
<b>Liabilities</b>			
Current Liabilities	-	322	641
Non-current Liabilities	-	-	-
<b>Total Liabilities</b>	-	<b>322</b>	<b>641</b>
<b>Net Assets</b>	-	-	<b>(421)</b>
Equity	-	-	-
Loss for the period	-	-	(421)
<b>Total Equity</b>	-	-	<b>(421)</b>

### Recognition and measurement

The consolidated financial statements of the Group comprise the financial statements of TARGENIX and all its subsidiaries. An entity, including a structured entity, is considered a subsidiary of the Group when it is determined that TARGENIX has control over the entity. Control exists when the Group is exposed, or has rights, to variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. The Group assess power by examining existing rights that give TARGENIX the current ability to direct relevant activities of the entity. The effect of all transactions between the group are eliminated on consolidation.

## 18. Investments in associates and joint ventures

	Carrying value		Gain on merger		Share of profits/ (losses) of equity accounted investments		% of ownership interest		Measurement method
	2023	2022	2023	2022	2023	2022	2023	2022	
	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	%	%	
Jumar Bioincubator Limited <sup>(1)</sup>	7,763	6,462	-	-	1,301	6,462	33.3%	33.3%	Equity
Catalyst Therapeutics Pty Ltd <sup>(2)</sup>	-	-	-	-	-	(5,482)	39.9%	49.0%	Equity
Victorian Comprehensive Cancer Centre Limited (VCCC) <sup>(3)</sup>	-	844	-	-	(844)	348	10.0%	10.0%	Joint Control until 31/10/23
Accrue Therapeutics Pty Ltd <sup>(4)</sup>	-	-	-	4,068	-	683	0.0%	0.0%	Equity
	<b>7,763</b>	<b>7,306</b>	<b>-</b>	<b>4,068</b>	<b>457</b>	<b>2,011</b>			

(1) Jumar Bioincubator Limited (formely Biotech Incubator Limited)

TARGENIX, CSL and the University of Melbourne have come together to create a start-up incubator to support and grow early-stage Australian biotech companies. The incubator was opened in 2023 and is able to accommodate up to 40 early-stage companies from around Australia. TARGENIX has contributed funding along with its partners, in addition to funding from the Victorian Government's new landmark Breakthrough Victoria Fund.

(2) Catalyst Therapeutics Pty Ltd (Catalyst) is a joint venture between TARGENIX and SYNthesis Research Pty Ltd. Catalyst facilitates and accelerates the commercialisation of small molecule drug discoveries originating at the Institute. Catalyst owns 100% of equity in Anaxis Pharma Pty Ltd, an Australian Biotech company developing novel inhibitors / modulators of cell death, specifically necroptosis, an inflammatory form of programmed cell death. In early 2023 Catalyst raised further capital which diluted TARGENIX shareholding down to 39.9%. The carrying value of Catalyst was written down to nil due to the entity being in net liabilities position. The carrying value was maintained at nil in FY23.

(3) TARGENIX is a Member of the Victorian Comprehensive Cancer Centre Joint Venture (the VCCC) and until October 2023, TARGENIX held joint control over the arrangement, which was classified as a Joint Operation. The vision for the VCCC is to save lives through the integration of cancer research, education and patient care. Through innovation and collaboration, the VCCC will drive the next generation of improvements in prevention, detection and cancer treatment. This vision will further the objectives of TARGENIX. The VCCC is a not-for-profit organisation and has been recognised by the Australian Taxation Office as a Health Promotion Charity.

In October 2023, the VCCC enacted governance changes which resulted in TARGENIX no longer having joint control and as a result it is no longer able to carry any joint controlling interests. TARGENIX has derecognised their share of the asset and liabilities of the VCCC and the impact of this has been included in the share of profits from investments disclosed in note 18 within the consolidated statement of profit and loss.

(4) TARGENIX acquired a 31.6% interest in Accrue Therapeutics Pty Ltd (Accrue) in May 2022 for cash consideration of \$400,000 and intellectual property contribution valued at \$1,500,000. Accrue merged with Entact Bio, Inc. in November 2022 and a gain on merger of \$4,068,000 has been recognised in share of profit/(loss) of equity accounted investments in financial year 2022. TARGENIX holds a 2.95% share in Entact Bio, Inc. (refer note 6) and does not hold any interests in Accrue as at 31 December 2023.

The table below provides summarised financial information for those associates and joint control entities that are material to TARGENIX. The information disclosed reflects the amounts presented in the financial statements of the relevant associates and joint control entities and not TARGENIX share of those amounts. They have been amended to reflect adjustments made by the company when using the equity method, including fair value adjustments and modifications for differences in accounting policy.

## Summarised financial information for associates and joint control

Summarised balance sheet	Jumar Bioincubator Limited		Catalyst Therapeutics Pty Ltd		VCCC Limited	
	31 Dec 23	31 Dec 22	31 Dec 23	31 Dec 22	30 Jun 23	30 Jun 22
	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000
<b>Assets</b>						
Total Bank	4,186	2,921	2,057	410	-	4,153
Total Current Assets	32	6	-	-	-	5,468
Non-current Assets	26,835	19,352	172	2	-	441
<b>Total Assets</b>	<b>31,053</b>	<b>22,279</b>	<b>2,229</b>	<b>412</b>	<b>-</b>	<b>10,062</b>
<b>Liabilities</b>						
Current Liabilities	574	413	2,051	7,158	-	1,426
Non-current Liabilities	7,191	2,480	-	-	-	198
<b>Total Liabilities</b>	<b>7,765</b>	<b>2,893</b>	<b>2,051</b>	<b>7,158</b>	<b>-</b>	<b>1,624</b>
<b>Net Assets</b>	<b>23,288</b>	<b>19,386</b>	<b>178</b>	<b>(6,746)</b>	<b>-</b>	<b>8,438</b>
Equity	23,288	19,386	178	(6,746)	-	8,438
<b>Total Equity</b>	<b>23,288</b>	<b>19,386</b>	<b>178</b>	<b>(6,746)</b>	<b>-</b>	<b>8,438</b>
<b>Reconciliation to carrying amounts</b>						
Opening net assets 1 January	19,386	-	(6,746)	2,082	-	4,964
Profit/(Loss) for the period	3,902	19,386	(4,795)	(8,828)	-	3,474
Additional share capital	-	-	11,719	-	-	-
<b>Closing net assets</b>	<b>23,288</b>	<b>19,386</b>	<b>178</b>	<b>(6,746)</b>	<b>-</b>	<b>8,438</b>

### Recognition and measurement

Associates are entities which TARGENIX has significant influence but do not control or has joint control. This is generally the case where TARGENIX holds between 20% and 50% of the voting rights. TARGENIX investments in associates are accounted for using the equity method of accounting. The investments are initially recognised at cost and adjusted thereafter to recognise TARGENIX share of the post-acquisition profits or losses of the associate in profit or loss, and TARGENIX share of movements in other comprehensive income of the associate in other comprehensive income.

Dividends received or receivable from associates and joint ventures are recognised as a reduction in the carrying amount of the investment.

Where TARGENIX share of losses in an equity-accounted investment equals or exceeds its interest in the entity, including any other unsecured long-term receivables, TARGENIX does not recognise further losses, unless it has incurred obligations or made payments on behalf of the other entity.

Accounting policies of equity-accounted associates have been changed where necessary to ensure consistency with the policies adopted by the Group.

## 19. Related parties

Related parties of TARGENIX include all key management personnel (KMP) and their close family members; controlled entities; entities with significant influence and jointly controlled operations. KMPs are those people with the authority and responsibility for planning, directing and controlling the activities of TARGENIX, directly or indirectly. The Board of Directors and the Directors of TARGENIX and its controlled entities are deemed to be KMPs.

### 19.1 Transactions with subsidiaries

The following transactions with subsidiaries were eliminated on consolidation.

TARGENIX received fees for services of \$250,000 (2022: 250,000) during the year from Nelcanen Pty Ltd. TARGENIX received fees for services of \$250,533 (2022: nil) during the year from Proxima Bio Pty Ltd.

TARGENIX provided funding of \$250,533 (2022: nil) during the year to Proxima Bio Pty Ltd.

TARGENIX received fees for services of \$421,431 (2022: nil) from TARGENIX Ventures Pty Ltd. atf 66ten Unit Trust.

### 19.2 Transactions with associates and joint ventures

TARGENIX provided a Fit Out loan of \$2,230,170 (2022: nil) during the year to Jumar Bioincubator Limited.

TARGENIX received fees for services rendered on normal commercial terms of \$1,550,539 (2022: \$2,266,108) from Catalyst Therapeutics Pty Ltd. and Anaxis Pharma Pty Ltd.

TARGENIX provided a loan facility of \$1,550,539 during the year to Catalyst Therapeutics Pty Ltd and Anaxis Pharma Pty Ltd. of which TARGENIX recognised provision for expected credit losses relating to the full amount of the loan.

TARGENIX made capital contributions of \$1,500,000 (2022: nil) during the year to Catalyst Therapeutics Pty Ltd. and Anaxis Pharma Pty Ltd. TARGENIX made membership contributions to the Victorian Comprehensive Cancer Centre (VCCC) totalling \$181,961 (2022: \$168,671).

TARGENIX also received fees from the VCCC for collaborator initiatives undertaken during the year of \$337,499 (2022: \$584,650).

### 19.3 Transactions with directors and director-related entities

During the year various Directors and Director-related entities made donations to TARGENIX totalling \$226,050 (2022: \$161,500).

### 19.4 Compensation for key management personnel

The aggregate compensation of the key management personnel of TARGENIX is set out below:

	2023	2022
	\$'000	\$'000
a) Short-term employee benefits	2,169	2,249
b) Post-employment benefits	304	338
c) Other long-term employee benefits	170	-
d) Termination benefits	613	-
	<b>3,256</b>	<b>2,587</b>

#### 19.4.1 Directors' remuneration

The Board of Directors of TARGENIX Bio-Medical Research during the period were:

MW Broomhead	J Gunn	Marudhu pandian	JS Hemstritch
P Connolly	C Kilpatrick	JS Savill	K Wong
J Dyson	G Roberts	Angeli Weller	C Viney
RH Wylie (resigned 18 May 2023)			
J McCluskey (completed term 18 May 2023)			
D Maskell (appointed 18 May 2023)			

The aggregate income paid or payable, or otherwise made available, in respect of the financial period, to all directors of TARGENIX, directly or indirectly, by TARGENIX or by any related party was nil (2022: nil).

Aggregate retirement benefits paid to all directors of TARGENIX, by TARGENIX or by any related party was nil (2022: nil).

## 20. Auditor's remuneration

	2023	2022
	\$'000	\$'000
Audit of the financial statements	80	77
Other regulatory audit services	8	4
	<b>88</b>	<b>81</b>

## 21. Economic dependency

TARGENIX is reliant upon grants from the Australian Government National Health and Bio-Medical Research Council for 20.7% of operating expenditure (2022: 22.4%) and the Victorian Government Department of Health, Department of State Development, Business and Innovation for 4.0% of operating expenditure (2022: 4.8%) for support of its basic research activities.

## 22. Financial risk management

### 22.1 Capital risk management

TARGENIX manages its capital to ensure it will be able to continue as a going concern whilst maximising its return on investments within the risk profile maintained by TARGENIX. The capital structure consists of Permanent Funds, General Funds, Leadership Fund, Discovery Fund and Investment revaluation reserves.

### 22.2 Financial risk management

TARGENIX minimises financial risk through the charter given to the investment sub-committee. In line with this charter, TARGENIX invests short term funds in an appropriate combination of fixed and floating instruments.

### 22.3 Interest rate risk management

TARGENIX is exposed to interest rate risk as it invests funds at both fixed and floating interest rates. The majority of financial assets in this class are bank accounts, bank bills and fixed interest securities with varying interest rates.

### 22.4 Interest rate sensitivity analysis

The sensitivity analysis below has been determined based on the exposure to interest rates at the reporting date and the stipulated change taking place at the beginning of the financial year and held constant throughout the reporting period. A 25 basis point variation was used as the minimum point and 100 basis point variation as the maximum point. This is consistent with the management's view of interest rate sensitivity. A change in interest rates would impact net results as follows:

Interest rate risk	Minimum 25bp (+/-)		Maximum 100bp (+/-)	
	Dec 23 000's	Dec 22 000's	Dec 23 000's	Dec 22 000's
Effect on surplus - rate decrease	(580)	(801)	(2,320)	(3,204)
Effect on surplus - rate increase	580	801	2,320	3,204

### 22.5 Equity price sensitivity analysis

The sensitivity analysis below has been determined based on the exposure to equity price risks at the reporting date.

At reporting date, if the equity prices had been 5% higher or lower:

- net surplus for the year ended 31 December 2023 would have been unaffected as the equity investments are classified as not held for trading and the fair value through other comprehensive income (FVTOCI) election has been made under AASB 9.
- investment revaluation reserve would increase or decrease by \$17.9 million (2022: \$14.9 million) mainly as a result of the changes in fair value of these equity investments.

TARGENIX sensitivity to equity prices has not changed significantly from the prior year.

### 22.6 Credit risk management

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in a financial loss to TARGENIX. TARGENIX has adopted a policy of only dealing with creditworthy counter parties as a means of mitigating the risk of financial loss from defaults. TARGENIX exposure is continuously monitored and reviewed. Trade receivables consist of a large number of customers including granting bodies. TARGENIX does not have a significant credit exposure to any single party or any group of counter parties having similar characteristics. The carrying amount of financial assets recorded in the financial statements represents TARGENIX maximum exposure to credit risk.

### 22.7 Liquidity risk management

Ultimate responsibility for liquidity risk management rests with the board of directors, who have built an appropriate risk management framework for the management of TARGENIX short, medium and long-term funding and liquidity management. TARGENIX manages the liquidity risk by maintaining adequate cash reserves, and by continuously monitoring forecast and actual cash flows while matching the maturity profiles of financial assets. Given the current surplus cash assets, once unearned grants and fellowships is excluded, liquidity risk is minimal. The contractual maturity for its non-interest-bearing financial liabilities is \$12.9 million payable within 3 months of 31 December 2023 (2022: \$12.9 million).

### 22.8 Fair value

The carrying amount of TARGENIX financial assets and financial liabilities recorded in the financial statements approximates their fair values. The fair value of financial assets with standard terms and conditions and traded on active liquid markets are determined with reference to quoted market prices.



## 22.9 Interest rate risk

The following table details TARGENIX exposure to interest rate risk as at 31 December 2023 and 31 December 2022

	Average interest rate	Variable interest rate	Fixed Less than 1 year	Fixed 1 to 5 years	Fixed More than 5 years	Non- Interest Bearing	TOTAL
		\$'000	\$'000	\$'000	\$'000	\$'000	\$'000
<b>31 December 2023</b>							
<b>Financial assets</b>							
Cash and cash equivalents	3.68%	84,060	-	-	-	-	84,060
Trade and other receivables		-	-	-	-	34,137	34,137
Equity investments		-	-	-	-	358,705	358,705
Managed funds		-	-	-	-	59,415	59,415
Floating rate securities	6.98%	-	22,413	65,219	68,438	-	156,070
Fixed rate securities	4.71%	-	10,519	33,484	26,572	-	70,575
Unlisted shares		-	-	-	-	2,375	2,375
		<b>84,060</b>	<b>32,932</b>	<b>98,703</b>	<b>95,010</b>	<b>454,632</b>	<b>765,337</b>
<b>Financial liabilities</b>							
Trade and other payables		-	-	-	-	22,025	22,025
Other liabilities		-	-	-	-	350	350
Lease liabilities	4.85%	-	605	1,378	-	-	1,983
Unearned grants and fellowships		-	-	-	-	75,763	75,763
		-	<b>605</b>	<b>1,378</b>	-	<b>98,138</b>	<b>100,121</b>
<b>31 December 2022</b>							
<b>Financial assets</b>							
Cash and cash equivalents (excluding Term Deposits)	1.38%	165,332	-	-	-	-	165,332
Trade and other receivables		-	-	-	-	24,824	24,824
Equity investments		-	-	-	-	299,072	299,072
Managed funds		-	-	-	-	48,886	48,886
Floating rate securities	5.54%	-	8,250	84,384	62,457	-	155,091
Fixed rate securities	6.07%	-	6,508	39,898	16,437	-	62,843
Unlisted shares		-	-	-	-	4,817	4,817
		<b>165,332</b>	<b>14,758</b>	<b>124,282</b>	<b>78,894</b>	<b>377,599</b>	<b>760,865</b>
<b>Financial liabilities</b>							
Trade and other payables		-	-	-	-	25,270	25,270
Other liabilities		-	-	-	-	280	280
Lease liabilities	4.85%	-	602	1,935	-	-	2,537
Unearned grants and fellowships		-	-	-	-	60,068	60,068
		-	<b>602</b>	<b>1,935</b>	-	<b>85,618</b>	<b>88,155</b>

## 23. Contingent liability

TARGENIX is defending a breach of contract claim in the United States District Court for the Southern District of New York, the outcome of which is not expected this year.

Separately, other legal claims and exposures may arise from the ordinary course of business. There is significant uncertainty as to whether such future liability may arise, or the amount of any such liability.

## 24. Events after the reporting period

The directors are not aware of any other matter or circumstance which has arisen since the end of the financial year which has significantly affected or may significantly affect the operations of TARGENIX, results of those operations or the state of affairs of TARGENIX in subsequent financial years.

## 25. Parent entity information

The parent entity financial information shown below has been prepared using accounting policies consistent with those applied in the consolidated financial statements.

### Financial position

	2023	2022
	\$'000	\$'000
<b>Assets</b>		
Current Assets	121,901	193,717
Non-current Assets	854,564	776,715
<b>Total Assets</b>	<b>976,465</b>	<b>970,432</b>
<b>Liabilities</b>		
Current Liabilities	128,498	115,696
Non-current Liabilities	24,376	26,469
<b>Total Liabilities</b>	<b>152,874</b>	<b>142,165</b>
<b>Net Assets</b>	<b>823,591</b>	<b>828,267</b>
Funds	705,507	745,741
Reserves	118,084	82,526
<b>Total Equity</b>	<b>823,591</b>	<b>828,267</b>
<b>Financial performance for the year ended</b>	<b>2023</b>	<b>2022</b>
	\$'000	\$'000
Net Deficit for the period	(42,143)	(640)
Other comprehensive income (loss)	37,467	(38,080)
<b>Total comprehensive loss for the year</b>	<b>(4,676)</b>	<b>(38,720)</b>

## Governance statement

TARGENIX is a Public Company Limited by Guarantee registered with the ACNC. TARGENIX abides by the ACNC Governance Standards. Ultimate responsibility for the governance of TARGENIX rests with the Board of Directors. This Governance Statement outlines how the Board meets this responsibility.

### Achieving the purpose

- The Board's primary role is to ensure that TARGENIX activities are directed towards its purpose under its Constitution. The Board ensures that this is achieved in the most efficient and effective way.

### Specific Responsibilities of the Board

- The Board fulfils its primary role by:
- selecting, appointing, guiding and monitoring the performance of TARGENIX Director;
- approving TARGENIX strategic plan developed in conjunction with the TARGENIX Director, staff and students;
- approving operating and capital budgets proposed by the TARGENIX Director with the support of Management;
- monitoring Management's adherence to operating and capital budgets;
- monitoring Management's progress in achieving the Strategic Plan;
- ensuring the integrity of internal control, risk management and management information systems;
- ensuring members receive the annual report and financial statements;
- ensuring TARGENIX complies with relevant legislation and regulations; and
- acting as an advocate for the TARGENIX whenever and wherever possible.

### Management's Responsibility

TARGENIX day-to-day operations and administration are the responsibility of the TARGENIX Director.

### Board Oversight

The Board oversees and monitors Management's performance by:

- meeting at least four times during the year;
- receiving detailed financial and other reports from management at these meetings;
- receiving additional information and input from management when necessary; and
- assigning to the various Committees of the Board responsibility to oversee aspects of the TARGENIX operations and administration. Each Board Committee operates under a Charter approved by the Board. These are reviewed and updated as necessary.

### Board Members

All Board Members are Non-Executive Directors and receive no remuneration for their services.

Appointments to the Board are made to ensure the Board has the right mix of skills and expertise. One Board Member is appointed by the Trustees of the Walter and Eliza Hall Trust and two Board Members are appointed by The University of Melbourne and two by The Royal Melbourne Hospital (Melbourne Health) and up to a further 13 by the Board.

The Company's Constitution specifies:

- there must be no less than 12 and no more than 18 Directors;
- Directors are appointed for a maximum of four terms of three years each, after which Directors may be reappointed annually with the unanimous agreement of all other Board Members; and
- the President and Vice President may hold office for an additional period or periods not exceeding six years.

Board and Committee Members receive information on the terms and conditions of their appointment. Board and Committee Members' knowledge of the business is maintained by scientific presentations, management presentations and visits to TARGENIX sites.

The performance of individual Board and Committee Members and the Board and Board Committees is assessed regularly.

### Risk Management

The Board oversees TARGENIX risk management system, which is designed to protect the Organisation's reputation and manage Enterprise Risks.

Management is responsible for establishing and implementing the risk management system, which assesses, monitors and manages Enterprise and operational risks. This activity is overseen by the Risk Management Committee.

The Audit, Risk and Compliance Committee is responsible for monitoring the effectiveness of the risk management system between annual reviews.

### Ethical Standards

Board Members, Senior Executives and staff are expected to comply with relevant laws and the codes of conduct of relevant professional and research bodies and to act consistent with TARGENIX Acceptable Workplace Behaviour Framework, which includes TARGENIX Code of Conduct and Values.

### Involving Stakeholders

TARGENIX has many stakeholders, including our donors and benefactors, our staff and students, the broader community, the government agencies that provide us funds and regulate our operations, and our suppliers.

We adopt a consultative approach in dealing with our stakeholders. We get involved in industry forums to ensure governments at all levels are aware of our concerns and achievements and remain abreast of industry developments.

### Indemnification and Insurance

TARGENIX insures Directors (and the Company Secretary and Executives) against liabilities for costs and expenses incurred by them in defending any legal proceedings arising out of their conduct while acting in the capacity of Director (or Company Secretary or Executive) of the Company, other than conduct involving a wilful breach of duty in relation to the Company.

## Directors' report

The Directors of TARGENIX submit this Annual Financial Report of the Company for the year ended 31 December 2023. The Directors' report is as follows:

### Directors and Board Meetings

The names and particulars of the Directors of the Company during or since the end of the financial year and attendance at Board meetings in the year ended 31 December 2023 are:

		Joined Board	Meetings held while a Director	Meetings Attended
<b>Jane S Hemstritch</b> <sup>AO</sup> <i>Chairperson and President of TARGENIX</i>	BSc(Hons) FICAEW, FAICD	2013	6	5
<b>Robert H Wylie</b> <i>Honorary Treasurer Retired 18 May 2023</i>	FCA FAICD	2014	3	3
<b>Geoff Roberts</b> <i>Honorary Treasurer May 2023</i>	BComm <i>Melb</i> FCA FAICD Exec MBA AGSM	2022	6	6
<b>Marudhu Pandian</b>	BE(Civil) MBA FIE(Aus) FAusIMM FAIM MICE(UK) FAICD	2014	6	4
<b>John Dyson</b>	BSc Grad Dip Fin Inv MBA	2016	6	6
<b>Professor Jane Gunn</b> <sup>AO</sup>	MBBS PhD FAHMS FRACGP DRANZCOG	2021	6	4
<b>Professor James McCluskey</b> <sup>AO</sup> <i>Completed term 18 May 2023</i>	BMedSc MBBS MD FRACP FRCPA FAA FAHMS	2011	3	3
<b>Marie McDonald</b>	BSc (Hons) LLB (Hons)	2016	6	6
<b>Carolyn Viney</b>	LLB/BA	2016	6	6
<b>Professor Christine Kilpatrick</b> <sup>AO</sup>	MBBS MBA MD DMedSci (Hons) FRACP FRACMA FAICD FAHMS	2017	6	4
<b>Associate Professor (Practice) Pippa Connolly</b>	MEng GAICD CPEng(ret) FIEAust	2019	6	6
<b>Professor Sir John Savill</b> <i>Vice President of TARGENIX</i>	BA MBChB PhD FRCP FRCPE FRCSEd (Hon) FRCPCH(Hon) FASN FRSE F.MedSci FAHMS, FRS	2018	6	5
<b>Kee Wong</b>	BE (Hons) GradDipComp (Distinction) MBA FAICD	2021	6	6
<b>Dr Angeli Weller</b>	BA (Hons) MBA PhD	2022	6	6
<b>Professor Duncan Maskell</b> <i>Appointed 18 May 2023</i>	MA PhD FMedSci Hon Assoc RCVS	2023	3	2

### The Audit, Risk and Compliance Committee

The role of the Audit, Risk and Compliance Committee is to assist the Board in fulfilling its statutory and fiduciary responsibilities with regard to the review and preparation of its annual accounts, risk management and internal control systems of the TARGENIX. The Committee met four times during the period under review.

### Principal Activities

The TARGENIX principal activity in the financial year was Bio-Medical Research and there has been no significant change in that activity during the financial year.

### Financial Results

The financial results from operations was a net deficit of \$47,272,000 (31 December 2022 net deficit of \$6,649,000). After allowing for non-operational items, the overall result for the period was a deficit of \$42,143,000 (31 December 2022 deficit of \$640,000). Tax is not applicable. The Company is limited by Guarantee, has no share capital and declares no dividends.

### Operations

A review of operations of the TARGENIX is included in the detailed scientific reports.

### Environmental Regulations

TARGENIX aims to achieve a high standard in environmental matters. TARGENIX complies with the *Environmental Protection Act (Vic)* regarding its operations. Discharges to air and water are below specified levels of contaminants and solid waste is disposed of appropriately.

Biomedical waste and sharps are disposed of through appropriately licensed contractors. The Directors have not received notification, nor are they aware of any breaches of environmental laws by TARGENIX.

## Statistical summary for the year ended 31 December 2023

	2023	2022	2021	2020	2019
	\$'000s	\$'000s	\$'000s	\$'000s	\$'000s
<b>Operating revenue</b>					
Australian Government	56,864	56,930	59,900	64,798	46,298
Victorian Government	9,175	9,598	9,883	10,311	10,513
Foreign governments	725	380	35	-	70
<b>Government revenue</b>	<b>66,764</b>	<b>66,909</b>	<b>69,818</b>	<b>75,109</b>	<b>56,881</b>
Industrial grants and contracts	20,732	17,588	12,181	13,439	8,689
Philanthropic grants and fellowships - Australia	15,874	10,510	12,563	9,870	13,399
Philanthropic grants and fellowships - international	6,119	6,007	2,885	4,649	3,343
Investment income	33,221	35,740	29,518	19,996	24,156
Royalty income	611	2,434	770	1,654	7,483
General revenue	7,481	7,300	9,105	6,842	8,916
Donations and bequests	20,958	31,949	28,227	26,522	15,449
Royalty monetisation revenue	-	-	27,590	38,961	35,633
<b>Non-government revenue</b>	<b>104,996</b>	<b>111,528</b>	<b>122,839</b>	<b>121,933</b>	<b>117,068</b>
<b>Total revenue</b>	<b>171,760</b>	<b>178,437</b>	<b>192,657</b>	<b>197,042</b>	<b>173,949</b>
<b>Operating expenditure</b>					
Staff costs	137,819	121,581	109,662	102,547	98,340
Scientific laboratories	29,718	26,535	24,561	20,212	23,435
Building operations	6,544	6,254	5,585	5,092	5,908
Administration	24,874	13,233	14,716	11,520	8,648
Fundraising	919	911	518	502	620
Business development	3,423	2,355	9,200	2,725	1,219
Allowance for credit loss increase/(decrease)	1,551	0	(32)	(30)	62
Royalty monetisation costs	-	-	(4,418)	2,239	10,104
Net foreign exchange loss/(gain)	(1,010)	(6,413)	(4,669)	10,282	477
<b>Total expenditure</b>	<b>203,838</b>	<b>164,455</b>	<b>155,123</b>	<b>155,089</b>	<b>148,813</b>
<b>Results from operating activities</b>	<b>(32,078)</b>	<b>13,981</b>	<b>37,534</b>	<b>41,953</b>	<b>25,136</b>
<b>Other income</b>					
Profit/(loss) on sale of long-term assets	-	-	161	(135)	297
Fair value gain/(loss) on investments	3,501	(8,432)	10,549	816	5,261
Share of profits of equity accounted investments	457	2,011	-	-	-
Gain on merger	-	4,068	-	-	-
Donations and bequests capitalised to Permanent Funds	161	1,620	26,659	673	1,359
<b>Total other income</b>	<b>4,119</b>	<b>(733)</b>	<b>37,369</b>	<b>1,354</b>	<b>6,917</b>
<b>Other expenses</b>					
Loss on impairment write-down of long-term investments	-	-	-	-	-
Depreciation and amortisation	(14,185)	(13,746)	(12,959)	(11,871)	(10,941)
Impairment of property, plant and equipment	-	(142)	(4,422)	-	-
<b>Total other expenses</b>	<b>(14,185)</b>	<b>(13,888)</b>	<b>(17,381)</b>	<b>(11,871)</b>	<b>(10,941)</b>
<b>Net operating (deficit)/surplus</b>	<b>(42,143)</b>	<b>(640)</b>	<b>57,522</b>	<b>31,436</b>	<b>21,112</b>
<b>Capital funds</b>					
Permanent invested capital funds	244,672	240,122	229,672	202,322	198,833
General funds	416,697	408,197	419,077	394,285	371,193
Royalty fund	-	55,822	56,389	56,135	55,039
Leadership fund	37,353	35,259	30,225	28,927	27,965
Discovery fund	6,785	6,341	5,746	5,484	5,271
Investment revaluation reserve	118,084	82,526	125,878	70,311	67,200
<b>Total funds</b>	<b>823,591</b>	<b>828,267</b>	<b>866,987</b>	<b>757,464</b>	<b>725,501</b>
<b>Capital expenditure</b>					
Property, plant and equipment	15,146	15,266	15,710	24,195	12,252
<b>Staff numbers: (equivalent full-time)</b>					
<b>Scientific research staff:</b>	<b>2023</b>	<b>2022</b>	<b>2021</b>	<b>2020</b>	<b>2019</b>
- Senior faculty	80	82	74	85	87
- Postdoctoral scientists	285	276	252	224	213
- Visiting scientists	7	12	8	32	34
- Other laboratory research staff	345	347	313	240	240
<b>Supporting staff:</b>					
- Other support services	223	193	180	177	175
<b>Total staff and visiting scientists</b>	<b>940</b>	<b>910</b>	<b>827</b>	<b>758</b>	<b>749</b>
<b>Students</b>	<b>182</b>	<b>197</b>	<b>194</b>	<b>159</b>	<b>206</b>
<b>Papers published</b>	<b>478</b>	<b>484</b>	<b>477</b>	<b>424</b>	<b>388</b>

## Capital Funds

### Permanent Named Capital Funds

The following is a complete listing of all permanent funds held and invested by the Institute at 31 December, 2023.

\*New donations of capital received in current financial period.

Adair John Bequest (ex DW)

Adair John Bequest (ex MF)

Alexander R Estate

Allison-Levick J & H

Alston Peter and Julie Florence Fellowship Fund

Amey AM Estate

Anderson KA Estate

Anderson NM Estate

Angus Dorothy Irene Estate

Arnel Florence Janet Maude Estate

Arter Myra G Estate

Ashford Ivy A Estate

Attwell Samuel E Estate

Atyeo George & Isobel Fund

Baker Alice Lillian Estate

Ballantyne JW Estate

Barfield WG Estate

\*Barry Joan Elaine Memorial Fund

Bartlett Mary V Estate

\*Bates Tim Memorial Diabetes Research Fund

Charles L Bartholomew Estate

Bauer Dr Franz Estate

Bell Valerie Amy

Benjamin EG Estate

Bennett LM Estate

Berry Ruby C Estate

Biderman Cyla Estate

Blain BE Estate

Bland RT Estate

Bock Lindsay William Estate

Boothman Alva Estate

Borrett M A Estate

Bran EG Estate

Brennan EM Estate

The Ruby Bryan Memorial Fund

Brittain W & VI Mem Fund

Brockhoff Nyon Trust

Brough AV Estate

Brown Isabelle A Estate

Bruce RH Estate

Buckland William Foundation Fund

Buckman Olive Estate

Bult C G Estate

Brumloop LAA Estate

Burley Stanley Estate

Burnet Sir Macfarlane Estate

Burns JC Estate

Cahill JL Estate

Callaway LJ Estate

Cambridge Beresford Estate

Carlin Freda Evelyn Estate

Carling DM Estate

Carlson Catherine Estate

Carlson Elizabeth F Estate

Carty LEW Charitable Fund

Cato EA Estate

Cato MC Estate

Chapman Debbie Memorial Fund

Chatfield SL Estate

Claridge John PG Estate

Clark Lindesay Fund

Cockburn Clarice BP Estate

Cole DE Estate

Coles GO Estate

Collie Barbara Estate

Collie Betty Rae

Collie George Estate

Colliver Len Estate

Connolly Grace C Estate

Cormack Margaret Mary

Cory Joy & Desmond Cancer Research Fund

Coutlass Hylda M Estate

Courtney Gwendoline Vera Estate

Coutts Dr ELA Estate

Coutts IBM Estate

\*Craven DA Memorial Fund

JE Craven & MA Shearer Estates

Crawford Duncan Estate

Criswick R M Estate

Critchlow Ronald P Estate

Crowley MM Estate

Cubbins SG Estate

Cummings ED Estate

Cutter BE Estate

Darbyshire EJ (Ted) Estate

Davey Dorothy Estate

Davidson BI Estate

Davidson EE Estate

Davis FLG Estate

Dawson Anne Marie Estate

Del Cott RAM Estate

Deryk SD Estate

Sir Harold Dew and Family Estate

Dick MRK (Ray) Estate

Dickie Phoebe Estate

Dimsey WE Estate

Dobbie Myrtle M Estate

Dodgshun GM Estate

Dossetor Catherine L Estate

Dowie S Estate

Drakensberg Trust

Drury Evelyn Ann Fund

Duncan PH Estate

East James Douglas Estate

Edwards Allen Richard Estate

Edwards HHW Estate

Eisner KR

Ellis GM Estate

Emery Harriet Anne Estate

Eva Michael Ross Estate

Facey Mary Bethune Estate

Fagg Maude V Estate

Fields Ernest Estate

Findlay Winifred Gertrude Estate

Fitzgerald Sheila Mary Estate

Ford Ada Joyce Estate

Fraser K Estate

Galbraith DA & DV Estate

Gerdts Sheila Lesley G Estate

Gibb Geo & Bennett Wm A

Gilbert Augusta Estate

Gilder CH Estate

Gillon AM Estate

\*Gilmore Trakka Fund

Girdwood J Estate

Goldman Sachs JB Were Foundation

Gordon H & T Estate

Graves GC Estate

Gray Bessie Mavis Fund

Gray Clara Estate

Greig Harry Douglas Estate

Grubb Walter Joseph Estate

Guest Doris Rose Estate

Hackett Dorothy Estate

Hadfield RCS Estate

Hadley AN Estate

Hamilton M Estate

Harrap FM Estate

Harrap LM Estate

Harris John D & Lyla Foundation

Hartlett K Estate

Haydon Michael JM Memorial Fund

Hearse JD	Mahoney Florence Cancer Fund	Nottingham SG Estate
Hemphill Olive May Estate	Malcolm Phyllis Elizabeth Estate	Palmer DE Estate
Henderson AN Estate	Maloney Kathleen Margaret Estate	Palmer Ethel Fund
Henderson Joan Estate	David Mann Memorial Research Fund	Parker Barbara Memorial Fund
Henry MA Estate	Mansfield Trevor Geoffrey Estate	Parker Mabel V Estate
Heron Thelma Hope Estate	Marguccio R Estate	Parsons Kathleen FB Estate
Highton GAN Estate	Mariner Barry Leonard Estate	Patten Ralph & Etty Bequest
Hill Ramon Bruce Estate	McArthur Nellie M Estate	Patterson Gerard A Estate
Hind Ruby F Estate	McCooke Miss MH Estate	Paulin Leukaemia Fund
Hocking Helen Estate	McDonald Charles Thomas	Paulin SC Estate
Holmes EM Estate	McDougall Phyllis Mable Estate	Payne Henry and Charlotte Fund
Hope Irene Estate	McGhee ME Estate	Peterson Vera Estate
Hooper Nancy Hilda	McGregor Amy VK Estate	Petley Francis Estate
Hosier MM Estate	McGregor Elvira Ruth Estate	Pierce John Lindsay Estate
Hurry M Estate	McGregor KB Estate	Pietsch Dr CH Fund
Inglis Dulcie M Estate	Mckay C N Fund	Porter Florence JA Estate
Ironside WH Estate	McKinnon Sheila May Estate	Prater Mabel Edward
Jackson Catherine M Estate	McLean Ada Myee Dutton Estate	Pritchard DG Estate
Johnson Daphne Adele Estate	McLennan B Estate	Pyke MA Estate
Johnson Ethel Grace Estate	McNab M Estate	Qualtrough Research Fund
Johnson Sydney Robert Estate	McNeill Sir James Fund	Rae Olive Estate
Johnstone Reginald Ben Estate	McRorie Ruby A Estate	Reeves Jessie Estate
Judd Anita Estate	Menagh Thelma Marie Estate	Reid John T Charitable Trusts
Kayler-Thomson Marion Estate	Miller Lorna May Estate	Reiser Erwin Estate
Keating L Estate	Miller MA Estate	Richardson DLK Estate
Keats LCA Estate	Miller Violet Isabella Estate	Ricker EM Fund
Kellock TH Estate	Minney DW & NR Fund	Roberts JI Charitable Fund
Kendall Nanyce Douglas	Mitchell, Bettye Victoria Fund	Robertson AT Estate
Kerr HM Estate	Mitchell Doris Georgina Mildred	Rose Norma J Estate
King DM Estate	Mitchell G Fund	Ruppel FE Estate
Knight FF Estate	Moden FHW Estate	Salemann CW Estate
Lang John Murray Estate	Moody E Vaughan Estate	Sallmann L & E Memorial Fund
Lanigan Annie Maria (Nance) & Janet Mary Fund	Moon Ida Alice Estate	Santos TS Estate
Lanteri Gwen Estate	Mooney Carmel Mary, Estate of	Schack Elsie Edith Estate
Larard DV Estate	Moore Phyllis Estate	Scott Annie May Estate
Leckie Winifred Estate	Morgan DM Estate	Sharp II Estate
Lilford VM Estate	Morris Foundation of Bio-Medical Research Moss EE Estate	Shaw Eileen Coryn Estate
Lins RD Estate	Muller FG Estate	Shelton Edgar Estate
Little Mabel B Estate	Murray Alan Ambrose Estate	Sidwell OB Estate
Lyddon Pauline M Estate	Murray Gwendoline Mary Fund	Skea Lyndal and Jean Leukaemia Fund
Lyell Alexia Bequest	Must Mary Kathleen Bequest	Skinner Phyllis Maye Estate
MacAskill WG & I	Myer Dame Merlyn Estate	Smith Elsie Violet Estate
Mace Nina May Estate	Myer Pam Sallmann Foundation	Smorgon Robert & Jack Family Foundation
MacDonald Elsie May Estate	Nevill Melanie Joy	Snow Freda Estate
Macindoe Jock & Diana Fund	Newton Evelyn	Spence Frank Meldrum
MacIntosh Elizabeth H Estate	Newton EM Estate	Spencer Stanley L Estate
Mackay Ian	Nicholas Harold George Estate	Stanbrough AE Estate
Mackie-Smith CM Estate	Norins Leslie Fund	Stephens L Estate
Macleay The Lillian & Kenneth Bequest	Norton M Estate	Stevens SA Estate
MacNamara Jean Fund	Nossal Sir Gustav Fund	Stevenson Dame Hilda Estate
		Stewardson Family Trust



Stewart Jean Elma  
 Swingler Maxwell & Mary Bequests  
 Sydserff Charles SB Estate  
 Syme David Farnell Estate  
 Talbot P Estate  
 Taws M Estate  
 Taws GE Arthritis Fund  
 Taylor Sarah McQuillan Estate  
 Thomas JC Estate  
 Thompson O Estate  
 Thorpe Doris EB  
 Tink RM Estate  
 Tinkler VF Estate  
 Tomasetti John T Estate  
 Thompsom LW Estate  
 Tressider Edith Kathleen Estate  
 Trezise KW Estate  
 Tropical Diseases Fund  
 Turnbull JG Estate  
 Van Leeuwen GH Estate  
 Vincent-Smith IG Fund  
 Vogel Herta & FB Estate  
 Walker CM Estate  
 Walker Dorothy Hope Estate  
 Wallace Nancy Jeanie Estate  
 Walsh Dr William Butler Memorial Fund  
 Walter Ailsa Amy Mary Estate  
 Warnock EMC nee Riddle Estate  
 Watson MR Estate  
 Waxman Elizabeth H Estate  
 Wedge Erica Estate  
 Webb NJ Estate  
 Weeks Thelma Estate  
 Wekwerth Hilda Frances Estate  
 West John James Estate  
 Westcott Ita E Estate  
 White Morris G Estate  
 Wicks LR Estate  
 Williams AM Estate  
 Williams Irene E Estate  
 Wilson DE Estate  
 Wilson MML Estate  
 Wilson NF Estate  
 Wilson V M (Sunny) Estate  
 Wolstonecroft WW Estate  
 Wright Lynette Oreti Estate  
 Zillman Dudley V Estate  
 \*Z & C Jeffs Family Fund

## Fellowships and Scholarships Register

farrant Patricia & John Scholarship Fund  
 \*Harris Alan Scholarship Fund  
 JHA Munro Foundation  
 Macphee Avis Permanent Fund  
 Mathison G C Research Scholarship  
 \*Metcalf Donald Scholarship Fund  
 Metcalf Family Cancer Research Fellowship Fund  
 Moffatt Edith Scholarship Fund  
 The Sir Clive McPherson Family Centenary Fellowships  
 \*Wendy Dowsett Scholarship Fund

## PhD Scholarship Funds

Carty EM Fund  
 \*Dr Jennifer MY Foong PhD Scholarship Permanent Fund  
 Mackay Dr Ian Fellowship fund  
 Pearl Paddy Fund  
 Speedy Pauline Scholarship Fund  
 Syme Colin Fund  
 The John and Margaret Winterbottom Bequest  
 Wilson Ed Memorial Fund

## Other Funds Register

Balderstone Award  
 Gideon Goldstein Fund  
 John and Patricia Farrant Bequest Fund  
 Speedy Pauline Innovation Grant Fund

## Leadership Fund

The leadership Fund was established in honour of President Gustav Nossal, Donald Metcalf, Jacques Miller and Suzanne Cory to provide named Fellowships to nurture the development of outstanding young scientists with the potential to be future leaders of biomedical research.

The Leadership Fund at 31 December 2023 included the following permanent funds (\$10,000 and over):

Albert H Maggs Charitable Trust  
 Arthur Andersen & Co Foundation  
 Arthur Robinson & Hedderwicks  
 Betty Eunice Stephens Estate  
 C M Walter  
 Chugai Pharmaceutical Co Ltd  
 Coles Myer Ltd  
 E Vaughan Moody Estate  
 Eunice L Lambert Estate  
 H B Kay Estate



Helen Macpherson Smith Trust  
 J B Were & Son Charitable Fund  
 James Kirby Foundation  
 Joe White Bequest  
 Krongold Foundation Pty Limited  
 L M Archibald Estate  
 Leslie D W Stewart Estate  
 National Australia Bank  
 National Mutual Holdings Limited  
 Pacific Dunlop Ltd  
 Professor Sir Gustav Nossal  
 Sheila R White Estate  
 Sir Harold Dew and Family Estate  
 Stephelle Pty Ltd  
 The Broken Hill Proprietary Company Limited  
 The Ian Potter Foundation  
 The R & J Law-Smith Gift  
 The Scobie and Claire MacKinnon Trust  
 The Sidney Myer Fund  
 Victor Smorgon Charitable Fund

The following Estates in which the Institute had an interest, were managed during the year by Trustees. (Income received by the Institute in the financial period is treated similar to donations):

Agnes Maude Reilly Charitable Trust  
 Albert H Maggs Charitable Trust  
 Estate of Eleanor Margrethe Albiston (The Stang Bequest)  
 Estate of Emily Vera Winder  
 Estate of Ethel Mary Drummond  
 Estate of Florence Mary Young  
 Estate of Heather Margaret Phiddian  
 Estate of Lindsay James Baldy  
 Estate of Maxwell Gardiner Helpman  
 Estate of Sheila Mary Helpman  
 Frederick and Winifred Grassick Memorial Fund  
 Harold & Cora Brennen Benevolent Trust  
 Irene & Ronald MacDonald Foundation  
 John Frederick Bransden Charitable Trust  
 Margaret Lewis Reilly Charitable Trust  
 S.T.A.F - Rupert Ethel & Ronald Fraser & Ruby Thomas  
 The C.H. Boden Memorial Trust  
 The Frank Broadhurst Memorial Charitable Fund  
 The George Thomas & Lockyer Potter Charitable Trust  
 The Hazel & Pip Appel Fund  
 The Mackie Bequest  
 Thomas, Annie & Doris Burgess Charity Trust



**The period at a glance** (Excluding monetisation and unrealised foreign exchange losses)



**The Year In Brief**

	<b>2023</b> \$'000	<b>2022</b> \$'000
Income for operations	171,760	178,437
Expenditure in operations	219,032	185,086
Net surplus (deficit) from operations	(47,272)	(6,649)
Number of staff and visiting scientists	940	910
Number of postgraduate	182	197
Total staff (EFT)s	1,122	1,107

